TKIs, BTK inhibitors, cytokine receptor antagonists, JAK inhibitors, mTOR inhibitors, etc. can decrease the probability of CRS occurrence during CAR-T cell therapy, prevent adverse reactions, and improve the tolerance rates of patients. Here, BTK is linked to congenital rubella syndrome.